MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.5 EUR | 0.00% |
|
+2.60% | 0.00% |
| 07-01 | Merck, Orion Convert Ongoing Collaboration Into Exclusive Global License for Opevesostat | MT |
| 07-01 | Merck: license agreement with Orion Corp. for opevesostat | CF |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 323B | ||||||
| 816B | ||||||
| 634B | ||||||
| 351B | - | - | - | - | ||
| 293B | ||||||
| 238B |
